Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05255445 · ClinicalTrials.gov registry record
Red Blood Cell - IMProving trAnsfusions for Chronically Transfused Recipients
A clinical trial of Sickle Cell Disease and Pediatric Cancer, sponsored by Westat.
- Completed
- Registry status
- 157
- Enrollment target
- 14
- Study locations
NCT05255445 is a study of Sickle Cell Disease and Pediatric Cancer that has completed, run by Westat. The registered enrollment target is 157 participants, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (46% lower). The trial reports 14 study locations across 8 states.
The verdict
NCT05255445, a study of Sickle Cell Disease and Pediatric Cancer, has completed, sponsored by Westat.
- COMPLETED
- Registry status
- 157 participants
- Enrollment target
- 14
- Study locations
Study Summary
Red Blood Cell - IMProving trAnsfusions for Chronically Transfused recipients (RBC-IMPACT) is an observational cohort study to assess donor, component, and recipient factors that contribute to RBC efficacy in chronically and episodically transfused patients. The objective of the study is to determine how specific genetic and non-genetic factors in donors and recipients may impact RBC survival after transfusion - in short, what factors on both the donor and recipient side may improve the efficacy of the transfusion.
Conditions Studied
Interventions
- BIOLOGICAL Red Blood Cell (RBC) Transfusion
Study Locations (14)
New York
- Weill Cornell Medical Collection (WCMC)/New York Presbyterian Hospital (NYPH) - New York
- Columbia University Irving Medical Center/New York Presbyterian Hospital (NYPH) - New York
- New York Blood Center (NYBC) - New York
Wisconsin
- Children's Wisconsin - Milwaukee
- Froedtert Hospital - Milwaukee
- Versiti Wisconsin, Inc. - Milwaukee
California
- UCSF Benioff Children's Hospital - Oakland
- Vitalant Research Institute - San Francisco
Other
- HEMORIO - Rio De Janeiro - Rio de Janeiro
- Childrens Institute and Adult Clinics at Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo - São Paulo
Massachusetts
- Boston Children's Hospital - Boston
Amazonas
- HEMOAM - Amazonas - Manaus
Minas Gerais
- HEMOMINAS - Minas Gerais - Belo Horizonte
Pernambuco
- HEMOPE - Pernambuco - Recife
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 157 participants |
| Start Date | 2022-03-16 |
| Est. Completion | 2024-03-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05255445
The ClinicalTrials.gov registry entry for NCT05255445 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 157 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (46% lower). The listed sponsor is Westat, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Sickle Cell Disease appearing as the primary indexed condition, and to 1 intervention - of which Red Blood Cell (RBC) Transfusion is the first listed.
NCT05255445 reports 14 study locations spanning 8 distinct geographic areas - top geographies include New York, Wisconsin, California.
Frequently Asked Questions
What is clinical trial NCT05255445 about?
NCT05255445 is a clinical study titled "Red Blood Cell - IMProving trAnsfusions for Chronically Transfused Recipients". Red Blood Cell - IMProving trAnsfusions for Chronically Transfused recipients (RBC-IMPACT) is an observational cohort study to assess donor, component, and recipient factors that contribute to RBC efficacy in chronically and episodically transfused patients. The objective of the study is to determin...
What is the current status of trial NCT05255445?
This trial is currently completed. The enrollment target is 157 participants. The study started on 2022-03-16. Estimated completion is 2024-03-31.
What conditions does trial NCT05255445 study?
This clinical trial studies the following conditions: Sickle Cell Disease, Pediatric Cancer, Thalassemia.
What interventions are being tested in trial NCT05255445?
The interventions under investigation include: Red Blood Cell (RBC) Transfusion (BIOLOGICAL).
Who is sponsoring clinical trial NCT05255445?
This trial is sponsored by Westat, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05255445 being conducted?
This trial has 14 study locations across California, Massachusetts, New York, Wisconsin, Amazonas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
RECRUITING · Phase 2
-
Early Life Exposures Among Children With Sickle Cell Disease
RECRUITING · NA
-
Exercise in Child Health
RECRUITING · NA
-
Sickle Cell Children's Exercise Study (SuCCESs)
RECRUITING · NA
-
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
RECRUITING · Phase 1
-
Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.